Concepedia

Toru Yoshinari

TY

Statistics

Publications

12

Citations

993

H-Index

12

Active since

2011

Affiliations

Mitsubishi Tanabe Pharma Corporation(Current)

Tokyo Medical and Dental University

Keio University

Mitsubishi Group (Japan)

Saitama Medical University

Toru Yoshinari is an author at Mitsubishi Tanabe Pharma Corporation specializing in pharmacotherapy, medicine, and clinical pharmacology.

Publications per year

2011–2020

12

Publications

12

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

Tsutomu Takeuchi, Yoshihiko Tatsuki, T. Yano et al. · Annals of the Rheumatic Diseases · 2011 · 152 citations · Full text

, , +17

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study

Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari et al. · Diabetes Obesity and Metabolism · 2013 · 137 citations · Full text

, , +17

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari et al. · Expert Opinion on Pharmacotherapy · 2014 · 123 citations

, , +13

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study

Yoshiya Tanaka, Masayoshi Harigai, Tsutomu Takeuchi et al. · Annals of the Rheumatic Diseases · 2011 · 115 citations · Full text

, , +13

Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

Takashi Wada, Masaya Inagaki, Toru Yoshinari et al. · Clinical and Experimental Nephrology · 2020 · 87 citations · Full text

, , +17

1–5 of 12